These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 24830188)

  • 1. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program.
    Greer GR; Grob CS; Halberstadt AL
    J Psychoactive Drugs; 2014; 46(1):73-7. PubMed ID: 24830188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabis for posttraumatic stress disorder: A neurobiological approach to treatment.
    Krumm BA
    Nurse Pract; 2016 Jan; 41(1):50-4. PubMed ID: 26678423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder.
    LaFrance EM; Glodosky NC; Bonn-Miller M; Cuttler C
    J Affect Disord; 2020 Sep; 274():298-304. PubMed ID: 32469819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Long-Term, Prospective, Therapeutic Impact of Cannabis on Post-Traumatic Stress Disorder.
    Bonn-Miller MO; Brunstetter M; Simonian A; Loflin MJ; Vandrey R; Babson KA; Wortzel H
    Cannabis Cannabinoid Res; 2022 Apr; 7(2):214-223. PubMed ID: 33998874
    [No Abstract]   [Full Text] [Related]  

  • 5. [Evaluation of Post-traumatic Stress Disorder: validation of a measure, the PCLS].
    Yao SN; Cottraux J; Note I; De Mey-Guillard C; Mollard E; Ventureyra V
    Encephale; 2003; 29(3 Pt 1):232-8. PubMed ID: 12876547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review.
    Orsolini L; Chiappini S; Volpe U; Berardis D; Latini R; Papanti GD; Corkery AJM
    Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31450833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of posttraumatic stress disorder in Cambodian refugees using the Clinician-Administered PTSD Scale: psychometric properties and symptom severity.
    Hinton DE; Chhean D; Pich V; Pollack MH; Orr SP; Pitman RK
    J Trauma Stress; 2006 Jun; 19(3):405-9. PubMed ID: 16788999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label assessment of aripiprazole in the treatment of PTSD.
    Robert S; Hamner MB; Durkalski VL; Brown MW; Ulmer HG
    Psychopharmacol Bull; 2009; 42(1):69-80. PubMed ID: 19204652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divalproex in posttraumatic stress disorder: an open-label clinical trial.
    Clark RD; Cañive JM; Calais LA; Qualls CR; Tuason VB
    J Trauma Stress; 1999 Apr; 12(2):395-401. PubMed ID: 10378177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study to evaluate the efficacy of aripiprazole as a monotherapy in patients with severe chronic posttraumatic stress disorder: an open trial.
    Villarreal G; Calais LA; Cañive JM; Lundy SL; Pickard J; Toney G
    Psychopharmacol Bull; 2007; 40(2):6-18. PubMed ID: 17514183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of civilian and combat-related posttraumatic stress disorder with topiramate.
    Andrus MR; Gilbert E
    Ann Pharmacother; 2010 Nov; 44(11):1810-6. PubMed ID: 20923947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial.
    Pollack MH; Hoge EA; Worthington JJ; Moshier SJ; Wechsler RS; Brandes M; Simon NM
    J Clin Psychiatry; 2011 Jul; 72(7):892-7. PubMed ID: 21367352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A preliminary controlled trial of divalproex in posttraumatic stress disorder.
    Hamner MB; Faldowski RA; Robert S; Ulmer HG; Horner MD; Lorberbaum JP
    Ann Clin Psychiatry; 2009; 21(2):89-94. PubMed ID: 19439158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabis and Complex Posttraumatic Stress Disorder: A Narrative Review With Considerations of Benefits and Harms.
    Dagan Y; Yager J
    J Nerv Ment Dis; 2020 Aug; 208(8):619-627. PubMed ID: 32433200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychometric properties of a Swedish translation of the Clinician-Administered PTSD Scale--Diagnostic Version.
    Paunović N; Ost LG
    J Trauma Stress; 2005 Apr; 18(2):161-4. PubMed ID: 16281209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the SPRINT and CAPS assessment scales for posttraumatic stress disorder.
    Vaishnavi S; Payne V; Connor K; Davidson JR
    Depress Anxiety; 2006; 23(7):437-40. PubMed ID: 16841342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and considerations for treating PTSD with medicinal cannabis: the Australian clinician's perspective.
    Ney LJ; Akosile W; Davey C; Pitcher L; Felmingham KL; Mayo LM; Hill MN; Strodl E
    Expert Rev Clin Pharmacol; 2023; 16(11):1093-1108. PubMed ID: 37885234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD.
    Bonn-Miller MO; Babson KA; Vandrey R
    Drug Alcohol Depend; 2014 Mar; 136():162-5. PubMed ID: 24412475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The accuracy of the Clinician-Administered PTSD Scale (CAPS) to identify PTSD cases in victims of urban violence.
    Pupo MC; Jorge MR; Schoedl AF; Bressan RA; Andreoli SB; Mello MF; de Jesus Mari J
    Psychiatry Res; 2011 Jan; 185(1-2):157-60. PubMed ID: 20537403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive posttraumatic stress disorder screens among first-time medical cannabis patients: prevalence and association with other substance use.
    Bohnert KM; Perron BE; Ashrafioun L; Kleinberg F; Jannausch M; Ilgen MA
    Addict Behav; 2014 Oct; 39(10):1414-7. PubMed ID: 24930048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.